An inherent limitation in the preclinical use of AE105 is its strict species-specificity (does not bind mouse uPAR), which complicates the evaluation of undesired toxic side effects such as nephrotoxicity in mouse models using human tumor xenografts [161]. Here, PLAUR is linked to neoplasm.